Tharimmune to Present at the Microcap Conference 2025
-
Sinner grateful for 'amazing' support on Italian Open return from doping ban
-
Hamburg return to Bundesliga after seven-year absence
-
Toulouse's Ntamack suffers concussion in Top 14 clash
-
India, Pakistan reach ceasefire -- but trade claims of violations
-
'Long time coming': Bayern's Kane toasts breakthrough title
-
US, China conclude first day of trade talks in Geneva
-
Kane tastes first title as champions Bayern bid farewell to Mueller
-
Benfica deny Sporting to take Portuguese title race to wire
-
Sinner makes triumphant return from doping ban at Italian Open
-
Sinner wins at Italian Open in first match since doping ban
-
Leo XIV, new pope and 'humble servant of God', visits Francis's tomb
-
India claims Pakistan violated truce, says it is retaliating
-
Champions League race hots up as Man City held, Villa win
-
Kane tastes first title as champions Bayern see off Mueller
-
US envoy calls enrichment 'red line' ahead of new Iran talks
-
Hastoy lifts La Rochelle as Castres pay tribute to Raisuqe
-
Southampton avoid Premier League 'worst-ever' tag with Man City draw
-
Injury forces Saints quarterback Carr to retire
-
S.Korea conservative party reinstates candidate after day of turmoil
-
Verdict due Tuesday in Depardieu sexual assault trial
-
Man City held by Southampton as Brentford, Brighton win
-
Groundbreaking Cameroonian curator Kouoh dies: Cape Town art museum
-
Leo XIV, 'humble servant of God', visits sanctuary in first papal outing
-
Leipzig miss Champions League as Bochum and Kiel relegated
-
Tarling wins Giro time trial in Tirana, Roglic in pink
-
US and China meet in 'important step' towards de-escalating trade war
-
Champions Chelsea finish WSL season unbeaten
-
At his former US university, the new pope is just 'Bob'
-
Ukraine allies set ultimatum to Russia for 30-day ceasefire
-
Deja vu in France as Marc Marquez beats brother Alex in MotoGP sprint
-
Alonso has 'every door open': Real Madrid's Ancelotti
-
Swiatek's Rome title defence ends early as Sinner set for hero's return
-
Marc Marquez wins French MotoGP sprint race
-
Swiatek's Italian Open title defence ended early by Collins
-
Uproar as S. Korea conservatives switch presidential candidate
-
Vollering retains women's Vuelta title in style
-
India and Pakistan agree to ceasefire after days of attacks
-
Pope Leo XIV says choice of name reflects social commitment
-
Ecuador declares national mourning for 11 troops killed by guerrillas
-
Thousands in Spain confined indoors for hours by toxic fumes
-
Postecoglou 'hopeful' Son will return for Spurs against Palace
-
Ukraine, Europe allies seek 30-day Russia truce starting Monday
-
Flick wants 'dominant' Barca in vital Liga Clasico
-
Panicked Indians flee Kashmir city on special train
-
With papacy, Leo XIV inherits Vatican money troubles
-
Quartararo pips Marquez brothers to pole at home French MotoGP
-
Indian town mourns young twins killed in Pakistani shelling
-
'Pragmatic' approach could reap 'ambitious' UK-EU deal: Starmer
-
Thousands confined indoors by toxic chlorine cloud in Spain
-
US and China meet in bid to 'de-escalate' trade war
NYSE - LSE
Tharimmune to Present at the Microcap Conference 2025
BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.
Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.
Event: The Microcap Conference 2025
Location: Studio 4, Borgata Hotel Casino & Spa
Date: Thursday January 30, 2025
Time: 10:00 AM Eastern Time
Investors interested in meeting with management can register for the conference here.
About Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to treating autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.
Contacts
Tharimmune, Inc.
[email protected]
Alliance Advisors IR
Tirth T. Patel
[email protected]
212-201-6614
Contact Information
Tirth Patel
Alliance Advisors IR
[email protected]
1-212-201-6614
SOURCE: Tharimmune Inc.
View the original press release on ACCESS Newswire
M.A.Colin--AMWN
